The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 40, 2008, Pages 15564-15569

  Thomas, Elizabeth A ^a   Coppola, Giovanni ^b   Desplats, Paula A ^a   Tang, Bin ^a   Soragni, Elisabetta ^a   Burnett, Ryan ^a   Gao, Fuying ^b   Fitzgerald, Kelsey M ^a   Borok, Jenna F ^a   Herman, David ^a   Geschwind, Daniel H ^b   Gottesfeld, Joel M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chromatin; Epigenetic; Neurodegenerative; Therapeutic; Trinucleotide

Indexed keywords

ALANINE GLYOXYLATE AMINOTRANSFERASE; ANGIOTENSINOGEN; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CCR6; HISTONE DEACETYLASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR 4B; HISTONE H3; HUNTINGTIN; MESSENGER RNA; METALLOTHIONEIN III; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN CORTEX; C57BL 6 MOUSE; CBA MOUSE; CEREBELLUM; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MALE; MICROARRAY ANALYSIS; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANILIDES; ANIMALS; CHROMATIN IMMUNOPRECIPITATION; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; PHENOTYPE; TRANSCRIPTION, GENETIC;

MUS MUSCULUS;

EID: 55749103407     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0804249105     Document Type: Article

References (34)

1. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983.
2. Sugars KL, Rubinsztein DC (2003) Transcriptional abnormalities in Huntington disease. Trends Genet 19:233-238.
3. Okazawa H (2003) Polyglutamine diseases: A transcription disorder? Cell Mol Life Sci 60:1427-1439.
4. Thomas EA (2006) Striatal specificity of gene expression dysregulation in Huntington's disease. J Neurosci Res 84:1151-1164.
5. Li SH, et al. (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 22:1277-1287.
6. Dunah AW, et al. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296:2238-2243.
7. Luthi-Carter R, et al. (2000) Decreased expression of striatal signaling genes in amouse model of Huntington's disease. Hum Mol Genet 9:1259-1271.
8. Freiman RN, Tjian R (2002) Neurodegeneration. A glutamine-rich trail leads to transcription factors. Science 296:2149-2150.
9. Zhai W, et al. (2005) In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 123:1241-1253.
10. Steffan JS, et al. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739-743.
11. Ferrante RJ, et al. (2004) Chemotherapy for the brain: The antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J Neurosci 24:10335-10342.
12. Ryu H, et al. (2006) ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc Natl Acad Sci USA 103:19176-19181.
13. Stack EC, et al. (2007) Modulation of nucleosome dynamics in Huntington's disease. Hum Mol Genet 16:1164-1175.
14. Desplats PA, et al. (2006) Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J Neurochem 96:743-757.
15. Hodges A, et al. (2006) Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 15:965-977.
16. Kuhn A, et al. (2007) Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 16:1845-1861.
17. Hockly E, et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 100:2041-2046.
18. Ferrante RJ, et al. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23:9418-9427.
19. Gardian G, et al. (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 280:556-563.
20. Kelly WK, O'Connor OA, Marks PA (2002) Histone deacetylase inhibitors: From target to clinical trials. Expert Opin Investig Drugs 11:1695-1713.
21. Dokmanovic M, Marks PA (2005) Prospects: Histone deacetylase inhibitors. J Cell Biochem 96:293-304.
22. Drummond DC, et al. (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:495-528.
23. Herman D, et al. (2006) Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2:551-558.
24. Rai M, et al. (2008) HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 3:e1958.
25. Hockly E, et al. (2003) Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res Bull 61:469-479.
26. Bates GP, Hockly E (2003) Experimental therapeutics in Huntington's disease: Are models useful for therapeutic trials? Curr Opin Neurol 16:465-470.
27. Beckers T, et al. (2007) Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 121:1138-1148.
28. Fennema-Notestine C, et al. (2004) In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology 63:989-995.
29. Broide RS, et al. (2007) Distribution of histone deacetylases 1-11 in the rat brain.JMol Neurosci 31:47-58.
30. Sadri-Vakili G, et al. (2007) Histones associated with downregulated genes are hypoacetylated in Huntington's disease models. Hum Mol Genet 16:1293-1306.
31. Mangiarini L, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506.
32. Fernagut PO, et al. (2002) Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: Behavioural and histopathological characterisation. Neuroscience 114:1005-1017.
33. Gentleman RC, et al. (2004) Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 5:R80.
34. Smyth GK (2005) Limma: Linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor, eds Gentleman R, et al. (Springer, New York), pp 397-420.